Literature DB >> 10473974

Role of endothelins in trinitrobenzene sulfonic acid-induced colitis in rats.

B M Güllüoglu1, H Kurtel, M G Güllüoglu, C Yegen, A O Aktan, F Dizdaroglu, R Yalin, B C Yegen.   

Abstract

To determine the role of endothelins (ET) on experimental colitis, following intracolonic trinitrobenzene sulfonic acid administration, rats were given orally either bosentan (BS), a nonselective ET receptor antagonist (100 mg/kg in 5% arabic gum), or arabic gum by gavage for 2 or 14 days. Macroscopic damage scores obtained in the vehicle (1.4+/-0.4), acute (4.8+/-0.6) and chronic (3.8+/-0.3) colitis groups were significantly higher than in the control group (0). BS treatment reduced the scores in both acute (3+/- 0.5) and chronic (2.3+/-0.5) colitis groups. Myeloperoxidase (MPO) activities of colonic tissues were elevated in acute and chronic colitis groups (325.1+/-44.9 and 431.8+/-54.6 U/g wet weight) as compared with the control group (73.6+/-11 U/g wet weight). Plasma protein oxidation levels were found to be significantly increased in the chronic colitis group (1,158.1+/-63.4 nmol/ml) compared with the control, ethanol and acute colitis groups (274.3+/-23.1, 490+/-52.2 and 422.2+/-50.5 nmol/ml). BS treatment significantly reduced both the protein oxidation level (375.5+/-46.9 nmol/ml) and MPO activity (167.5+/-35.8 U/g wet weight). The results of the present study suggest the involvement of ETs in the pathogenesis of colonic injury in this animal model of colitis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10473974     DOI: 10.1159/000007695

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

1.  Bosentan, an endothelin receptor antagonist, reduces leucocyte adhesion and inflammation in a murine model of inflammatory bowel disease.

Authors:  Christoph Anthoni; Rudolf B Mennigen; Emile J M Rijcken; Mike G Laukötter; Hans-Ullrich Spiegel; Norbert Senninger; Guido Schürmann; Christian F Krieglstein
Journal:  Int J Colorectal Dis       Date:  2005-08-09       Impact factor: 2.571

2.  Potential role for ET-2 acting through ETA receptors in experimental colitis in mice.

Authors:  R F Claudino; D F Leite; A F Bento; J G Chichorro; J B Calixto; G A Rae
Journal:  Inflamm Res       Date:  2016-10-24       Impact factor: 4.575

3.  Protective effects of black cumin (Nigella sativa) oil on TNBS-induced experimental colitis in rats.

Authors:  F Isik; Tugba Tunali Akbay; A Yarat; Z Genc; R Pisiriciler; E Caliskan-Ak; S Cetinel; A Altıntas; G Sener
Journal:  Dig Dis Sci       Date:  2010-07-24       Impact factor: 3.199

4.  Erdosteine prevents colonic inflammation through its antioxidant and free radical scavenging activities.

Authors:  Göksel Sener; Halil Aksoy; Ozer Sehirli; Meral Yüksel; Cenk Aral; Nursal Gedik; Sule Cetinel; Berrak C Yeğen
Journal:  Dig Dis Sci       Date:  2007-04-12       Impact factor: 3.199

5.  Endothelin-1 receptor antagonist (LU-135252) improves the microcirculation and course of TNBS colitis in rats.

Authors:  Martin Kruschewski; Tanja Anderson; Christoph Loddenkemper; Heinz J Buhr
Journal:  Dig Dis Sci       Date:  2006-07-26       Impact factor: 3.199

6.  Endothelin-2 deficiency causes growth retardation, hypothermia, and emphysema in mice.

Authors:  Inik Chang; Alexa N Bramall; Amy Greenstein Baynash; Amir Rattner; Dinesh Rakheja; Martin Post; Stephen Joza; Colin McKerlie; Duncan J Stewart; Roderick R McInnes; Masashi Yanagisawa
Journal:  J Clin Invest       Date:  2013-05-08       Impact factor: 14.808

7.  Endothelin and vascular remodelling in colitis pathogenesis--appendicitis and appendectomy limit colitis by suppressing endothelin pathways.

Authors:  Rajkumar Cheluvappa; Rajaraman Eri; Annie S Luo; Michael C Grimm
Journal:  Int J Colorectal Dis       Date:  2014-08-02       Impact factor: 2.571

8.  Effects of the endothelin-converting enzyme inhibitor SM-19712 in a mouse model of dextran sodium sulfate-induced colitis.

Authors:  Seungjun Lee; Patsy R Carter; Megan N Watts; Jianxiong R Bao; Norman R Harris
Journal:  Inflamm Bowel Dis       Date:  2009-07       Impact factor: 5.325

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.